The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been ...
Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 ...
7h
Zacks.com on MSNIONS’ Better-Than-Expected Q4 ResultsEC approves MRK's Welireg for two indications. FDA grants priority review to SNY and REGN's Dupixent sBLA for bullous pemphigoid.
As we approach the first anniversary of omalizumab’s approval for food allergy, its use is “definitely going to grow,” Robert ...
Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results